Links from this page to related variants, conditions, drugs and topics are not included for automated readers. Those connections are the Gene Knowledge Graph and are licensed as data: https://www.mygenelog.com/license
Five measurements — abdominal obesity, high triglycerides, low HDL, high blood pressure and high glucose — that cluster in the same people. Three independent studies, in three different populations, all asked whether that clustering shares a genetic cause and all three answered no, or close to it.
Metabolic syndrome is a clinical label rather than a single disease: a person is said to have it when they meet a threshold on several of five measurements at once — abdominal obesity, high triglycerides, low HDL ("good") cholesterol, high blood pressure, and high fasting blood glucose. Each of these raises cardiovascular disease and type 2 diabetes risk on its own, and having several together raises it further than the sum of the parts would suggest.
The obvious genetic question is whether this clustering has one shared cause — a gene or pathway that pushes several of these measurements at once — or whether it is five largely separate genetic stories that happen to co-occur, for reasons that may be more about diet, activity and body composition than about any single gene.
Three independent studies asked exactly this, in different populations, and reached the same answer. A 2010 study of Indian Asian men — a population with an unusually high prevalence of metabolic syndrome — tested genetic variation against the syndrome and its component traits directly. It found four SNPs reaching significance, in CETP and LPL, both already known to affect HDL cholesterol specifically, and concluded there was "little evidence of a common genetic basis" linking the components together.
A 2012 study of four Finnish cohorts — 2,637 cases and 7,927 controls — went further, explicitly testing whether any locus affected two or more unrelated components of the syndrome at once. One region, near the APOA1/C3/A4/A5 gene cluster, associated with the syndrome as a whole. Beyond that, 22 previously known loci for the individual component traits replicated — almost all of them lipid genes — and none moved two or more uncorrelated components together. The paper's own conclusion: genes from lipid metabolism pathways have the key role, and there is little evidence for pleiotropy linking dyslipidaemia and obesity to the other components, such as high blood pressure or glucose intolerance.
A 2011 study went furthest of all, and was designed for exactly this question from the start: it tested pairs of the syndrome's five components directly, in 22,161 participants, for common variants affecting both traits in a pair at once. Twenty-nine variants associated with the syndrome or a trait pair; among the sixteen strongest, one per gene — including a second LPL signal and a locus near BUD13 — none associated with more than two individual traits simultaneously, and together they explained only a small share of any one measurement's variance: about 9% of triglycerides, 5.8% of HDL cholesterol, 3.6% of fasting glucose, and 1.4% of systolic blood pressure.
All three papers behind this page name LPL — lipoprotein lipase, the enzyme that breaks down triglyceride-rich particles in the blood. This page holds two LPL variants — rs268 from the Finnish study and rs2083637 from the Indian Asian study, plus a third from the 2011 pairwise study, rs301 — alongside rs11820589 near BUD13 from that same study. It is the same gene already central to this site's high triglycerides page, which holds three further LPL variants of its own. Three independent studies, in three different populations, all landing on the gene this site already treats as a hub for triglyceride genetics is a form of replication in its own right — and it is also, on the evidence here, most of what "metabolic syndrome genetics" currently is: the genetics of the lipid component, rather than a genetics of the syndrome as an entity.
2026-07-14 · Stage-Dependent Genetic Association of the TyG Index with Cardiovascular-Kidney-Metabolic Syndrome Severity: A Genome-Wide Association and Mendelian Randomization Study. International Journal of Molecular Sciences. 2026. DOI:10.3390/ijms27146280
The triglyceride-glucose (TyG) index is a simple, cheap surrogate marker of insulin resistance calculated from routine bloodwork. This study asked whether it's more than just correlated with cardiovascular-kidney-metabolic (CKM) syndrome severity -- whether it's genetically causal. Using 107,161 Taiwan Biobank participants, it found the TyG index associated with advanced CKM stage severity (stages 3-4 combined) in standard regression. A separate GWAS in 104,778 participants identified the genetic determinants of the TyG index itself, and Mendelian randomization -- including a weighted genetic risk score and sample-split sensitivity analyses to guard against reverse causation -- supported a genuinely causal role for insulin resistance in worsening CKM staging, not merely an association that could run the other way. This is a mechanistic, population-scale validation of a cheap clinical marker's causal relevance, in an East Asian population where CKM staging research has been comparatively sparse. This site's metabolic syndrome page carries 11 variants; the TyG-specific genetic determinants identified here are not currently among them.
2026-01-19 · Unraveling the genetic interplay and therapeutic potentials between major depressive disorder and metabolic syndrome: multi-ancestry and multi-trait genome-wide association analyses. BMC Psychiatry. 2026. DOI:10.1186/s12888-026-07816-5
Major depressive disorder (MDD) and metabolic syndrome (MetS) frequently co-occur, and this study used GWAS datasets spanning European and East Asian populations to test the genetic relationship in both directions rather than assuming depression simply follows from metabolic illness or vice versa. It found bidirectional genetic correlations and shared pleiotropic genes between the two conditions, and cross-trait analysis strengthened the statistical robustness of new MDD-associated markers beyond what single-trait analysis alone would support. Using BLISS technology (a method for identifying disease-linked proteins from GWAS data), the study pinpointed proteins significantly linked to both conditions. Mendelian randomization further explored how differing dietary patterns across populations influence MDD and MetS risk. Most practically, computational drug-repurposing analysis flagged two existing drug classes as candidates worth investigating for both conditions: Cytochrome P450 inhibitors and HDAC (histone deacetylase) inhibitors -- neither currently used for depression or metabolic syndrome specifically, making this a genuinely novel repurposing angle rather than confirmation of an existing treatment relationship. The study's own summary did not specify individual gene or protein names in detail beyond the drug-class findings, so this site's major depressive disorder and metabolic syndrome pages record this as shared-biology and drug-repurposing context rather than new named variants.
2026-08-11 · Regeneron Genetics Center et al. Nature. 2026. DOI:10.1038/s41586-026-10864-2
A Regeneron-led analysis of over 1 million people across 11 studies in the Americas, Europe and Asia found that rare loss-of-function variants disabling FNIP1 -- which essentially turn the gene off -- associate with roughly 60% lower risk of heart disease and metabolic disorders in carriers of one copy. The effect tracked closely with a lower triglyceride-to-HDL-cholesterol ratio, and the authors confirmed FNIP1's role in lipid metabolism directly, using siRNA silencing in human liver cells and CRISPR-Cas9 deletion in mice. FNIP1 is not yet linked to any variant on this catalogue's coronary artery disease or metabolic syndrome pages -- the rare, protective loss-of-function variants this study analyzed are a different kind of finding from the common single-SNP associations this catalogue's Variant pages are built from, and are not yet represented at the rsID level here.
Diagnosis is a measurement exercise, not a genetic one: waist circumference, a blood pressure reading, and a blood draw for triglycerides, HDL cholesterol and fasting glucose, checked against threshold values from an established clinical definition. Meeting three or more of the five defining criteria is what constitutes the diagnosis. Management follows the same logic as its parts — weight loss, physical activity, and treatment of whichever specific component (blood pressure, lipids, glucose) is out of range.
What this page cannot do. The four variants here, three of them in LPL, shift lipid or glucose measures specifically and none of the three studies behind this page found a genetic explanation for the syndrome as a cluster. Metabolic syndrome is diagnosed by measurement, not by genotype, and nothing here changes that.
Three independent studies failing to find shared genetic loci across unrelated components of the syndrome does not mean no such loci exist — a larger study might still find one. But it is a meaningfully consistent finding across different populations and methods, and it points toward the syndrome's clustering being driven more by shared environmental and lifestyle exposures (diet, activity, body composition) acting on largely separate genetic systems, rather than by one genetic switch. That is a different and, so far, better-supported story than a single "metabolic syndrome gene."
The studies behind these variants recruited participants from different ancestries — a result found in one population doesn't always transfer to another. Based on 13 of 274 linked studies with a resolved discovery ancestry.
Databases, guidelines and references
Licensed CC BY-NC 4.0: free to read, share and adapt for non-commercial use, naming MyGeneLog™ and linking the exact page. Commercial use, including training or serving a commercial AI system, needs a licence — https://www.mygenelog.com/license
Metabolic Syndrome. MyGeneLog™. https://www.mygenelog.com/conditions/metabolic-syndrome
No. The four variants here each affect a specific lipid or glucose measurement, not the syndrome as a whole, and none of the three studies behind this page found a genetic basis for the syndrome as a cluster. Diagnosis is by measurement — waist circumference, blood pressure, triglycerides, HDL and fasting glucose — against an established clinical threshold.
They found real things — replicated lipid loci, including LPL three times over — but all three explicitly looked for genes that link the syndrome's different components together and did not find them. That is a real, consistent result across three populations, not an absence of findings.
Because it is a genuinely central gene in triglyceride metabolism, and all three genome-wide studies behind this page — in unrelated populations — independently landed on it. It is also the gene behind three further variants on this site's high-triglycerides page.
The leading alternative is that shared environmental and lifestyle exposures — diet, physical activity, body composition — act on several largely separate biological systems at once, producing the clustering without needing one shared genetic cause. None of the three studies here tested that directly, but it is consistent with what all three found.
Free to reuse, non-commercially. This page's text is original writing from freely-available research, licensed CC BY-NC 4.0 — share and adapt it with attribution to MyGeneLog™; commercial use is licensed. It's general research-derived information, not medical advice or a diagnosis — see Terms of Use.